Compare TNYA & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNYA | MBOT |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5M | 166.6M |
| IPO Year | 2021 | 2000 |
| Metric | TNYA | MBOT |
|---|---|---|
| Price | $0.77 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.33 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 2.8M | 1.3M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.96 | ★ 60.27 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.60 |
| 52 Week High | $2.35 | $4.62 |
| Indicator | TNYA | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 47.56 |
| Support Level | $0.64 | $2.34 |
| Resistance Level | $0.82 | $2.67 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 90.88 | 27.36 |
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.